Actinium Pharma Presents New Preclinical Data

Actinium Pharmaceuticals, Inc. will present new preclinical data for its drug candidates ATNM-400 and Actimab-A at the 2026 AACR Annual Meeting. The data highlights ATNM-400's potential in solid tumors and Actimab-A's differentiated mechanism for AML. As a pioneer in targeted radiotherapies, Actinium's ongoing research and development efforts are crucial for advancing its pipeline and demonstrating the efficacy of its innovative treatment approaches.